For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Unrealized loss on marketable securities | -48 | -23 | - | - |
| Total other comprehensive loss | -48 | -23* | - | - |
| Research and development | 25,031 | 10,502* | - | 23,368 |
| General and administrative | 6,086 | 4,785* | - | 4,424 |
| Total operating expenses | 31,117 | 15,287 | - | 27,792 |
| Loss from operations | -31,117 | -15,287* | - | -27,792 |
| Other income, net | 1,504 | 1,729* | - | 1,610 |
| Net Income Loss | -29,613 | -13,559* | -47,712 | -26,182 |
| Research and development | 25,031 | 38,287* | 44,931 | - |
| General and administrative | 6,086 | 4,785* | 4,568 | - |
| Total operating expenses | 31,117 | 43,072 | 49,499 | - |
| Loss from operations | -31,117 | -43,072* | -49,499 | - |
| Other income, net | 1,504 | 1,729* | 1,787 | - |
| Net loss | -28,225 | -41,344* | - | - |
| Total comprehensive loss | -29,661 | -54,926 | - | - |
| Basic EPS | -0.31 | -0.718 | -0.61 | -0.41 |
| Diluted EPS | -0.31 | -0.718 | -0.61 | -0.41 |
| Basic Average Shares | 89,814,820 | 76,491,122 | 78,324,767 | 64,027,892 |
| Diluted Average Shares | 89,814,820 | 76,491,122 | 78,324,767 | 64,027,892 |
Larimar Therapeutics, Inc. (LRMR)
Larimar Therapeutics, Inc. (LRMR)